By Sanofi, the renowned French pharmaceutical company, recently announced promising results from a clinical trial involving their cancer drug, Sarclisa. The trial evaluated the effectiveness of Sarclisa when used in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma who are eligible for transplantation.
According to Sanofi, the trial demonstrated a statistically significant improvement in the rate of minimal residual disease negativity. This term refers to the absence of myeloma cells in the bone marrow after treatment. Diagnostic techniques used to measure minimal residual disease negativity must have a sensitivity of at least 1 in 100,000 cells.
The combination therapy of Sarclisa and KRd showcased impressive results compared to KRd alone. Among patients where no cancer cells were detected within 100,000 bone marrow cells, the rate of minimal residual disease negativity was 77% for those treated with the combination therapy, while patients who received KRd alone achieved a 67% rate.
These promising results open up new possibilities for improved cancer treatment using Sarclisa in combination with other therapies. Sanofi continues to drive innovative research and development efforts in oncology to bring potential breakthroughs to patients in need.
Comments